Clinical Trials

Numerous clinical trials evaluate tamoxifen across early- to late-phase studies for oncology indications including estrogen receptor-positive breast cancer, ovarian cancer, glioblastoma, and hepatocellular carcinoma. Sponsored by academic medical centers such as Karolinska University Hospital and the University of Wisconsin, Madison, alongside pharmaceutical partners like Pfizer and Tolmar Inc., trial statuses encompass completed, actively recruiting, terminated, and withdrawn protocols. Overall, these investigations highlight the broad therapeutic scope of tamoxifen in managing hormone-dependent malignancies and refractory tumors.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07502820 RECRUITING
Breast Cancer; Adjuvant Drug Therapy
Karolinska Institutet
 2026-04-14 PHASE3
NCT06348134 RECRUITING
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; HER2-positive Breast Cancer; Breast Cancer
University of Chicago
 2025-03-18 PHASE2
NCT07190443 RECRUITING
Breast Cancer; Locoregional Recurrence; Abemaciclib; Endocrine Therapy
Japanese Foundation for Cancer Research
 2025-02-07 PHASE3
NCT05512364 RECRUITING
ER-positive Breast Cancer; HER2-negative Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
 2023-12-15 PHASE3
NCT06223698 NOT_YET_RECRUITING
Breast Cancer
Region Örebro County
 2025-05-02 PHASE3
NCT07729046 NOT_YET_RECRUITING
Metastatic Invasive Breast Cancer; Resistant Breast Cancer; ER+, HER2-, Metastatic Breast Cancer
University of California, San Diego
 2027-07 PHASE2
NCT07581834 RECRUITING
Breast Diseases; Breast Neoplasms; Dalpiciclib; Endocrine Breast Diseases; CDK4/6 Inhibitor; HR+/HER2- Breast Cancer
Fujian Cancer Hospital
 2026-01-21 PHASE2
NCT07101159 NOT_YET_RECRUITING
Early Breast Cancer; Adjuvant Therapy; Hormone Receptor Positive / HER2-negative Breast Cancer
Fujian Cancer Hospital
 2025-09 PHASE2
NCT07762885 RECRUITING
Ductal Carcinoma In Situ, DCIS
Fudan University
 2026-07-01 PHASE3
NCT04852887 RECRUITING
Stage I Breast Cancer
NRG Oncology
 2021-06-23 PHASE3
NCT06942039 RECRUITING
CNS Embryonal Tumor; CNS, Medulloblastoma; Atypical Teratoid Rhabdoid Tumor; Medulloblastoma, Childhood; Medulloblastoma, Group 3; Medulloblastoma, Group 4; Pineoblastoma; Neuroblastoma; Embryonal Tumor With Multilayered Rosettes; Embryonal Tumor With Abundant Neuropil and True Rosettes; Ependymoblastoma; Medulloepithelioma; CNS Embryonal Tumor With Rhabdoid Features; CNS Embryonal Tumor, Nos
C17 Council
 2025-09-23 EARLY_PHASE1
NCT07349069 RECRUITING
Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
 2026-03-04 PHASE3
NCT06671912 SUSPENDED
Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage 1 Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Estrogen Receptor-Positive Breast Carcinoma; HER2-Negative Breast Carcinoma; Breast Ductal Carcinoma In Situ; Breast Lobular Carcinoma In Situ
Alliance for Clinical Trials in Oncology
 2025-02-19 PHASE3
NCT07535905 NOT_YET_RECRUITING
Hypogonadism; Prostate Cancer
University Health Network, Toronto
 2026-07 PHASE2
NCT04584853 ACTIVE_NOT_RECRUITING
Breast Cancer Female
Institute of Cancer Research, United Kingdom
 2020-12-23 PHASE3
NCT05768139 RECRUITING
Breast Cancer; Solid Tumors, Adult
Eli Lilly and Company
 2023-04-17 PHASE1; PHASE2
NCT05161195 ACTIVE_NOT_RECRUITING
Metastatic Breast Cancer
Novartis Pharmaceuticals
 2022-07-07 PHASE4
NCT04134598 ACTIVE_NOT_RECRUITING
Breast Cancer
Azienda Ospedaliero-Universitaria Careggi
 2021-02-08 PHASE3
NCT05952557 ACTIVE_NOT_RECRUITING
Breast Cancer, Early Breast Cancer
AstraZeneca
 2023-10-05 PHASE3
NCT05645536 ENROLLING_BY_INVITATION
Breast Cancer
Tolmar Inc.
 2022-12-28 PHASE3
NCT06492616 RECRUITING
Breast Cancer
Stemline Therapeutics, Inc.
 2024-09-27 PHASE3
NCT06507618 RECRUITING
Breast Cancer Female
University of Virginia
 2024-07-19 PHASE3
NCT07019363 RECRUITING
Breast Cancer; Adjuvant Therapy
Fudan University
 2025-06-15 PHASE3
NCT06404775 NOT_YET_RECRUITING
Mastalgia
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
 2025-01-16 PHASE3
NCT07287098 RECRUITING
Breast Neoplasms
Eli Lilly and Company
 2026-05-13 PHASE2
NCT05035836 RECRUITING
Breast Cancer; HER2-positive
M.D. Anderson Cancer Center
 2021-11-16 PHASE2
NCT06361940 RECRUITING
Breast Cancer
Medical College of Wisconsin
 2024-09-30 PHASE2
NCT06434064 RECRUITING
Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable Triple-Negative Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma
Roswell Park Cancer Institute
 2026-03-03 PHASE2
NCT06320990 RECRUITING
Pancreatic Cyst; Pancreatic Mucinous Cystic Neoplasm
University of Nebraska
 2025-01-22 PHASE1
NCT06075953 RECRUITING
Ductal Carcinoma in Situ
QuantumLeap Healthcare Collaborative
 2024-02-17 PHASE2
NCT05891093 RECRUITING
Breast Cancer
Fudan University
 2023-06-01 PHASE3
NCT03011684 RECRUITING
Infertility
University of California, San Francisco
 2016-07-21 PHASE3
NCT06184750 RECRUITING
Breast Atypical Ductal Hyperplasia; Breast Atypical Lobular Hyperplasia; Breast Carcinoma; Breast Ductal Carcinoma In Situ; Breast Lobular Carcinoma In Situ; Estrogen Receptor-Positive Breast Carcinoma
National Cancer Institute (NCI)
 2024-09-27 PHASE2
NCT04740697 RECRUITING
Breast Cancer
Institut Claudius Regaud
 2021-02-12
NCT06979596 RECRUITING
Malignant Neoplasm
Merck Sharp & Dohme LLC
 2025-08-11 PHASE2
NCT05514054 ACTIVE_NOT_RECRUITING
Breast Neoplasms
Eli Lilly and Company
 2022-10-04 PHASE3
NCT04985266 RECRUITING
ER+ Breast Cancer; HER2-negative Breast Cancer
Royal Marsden NHS Foundation Trust
 2022-03-30 PHASE2
NCT07499999 NOT_YET_RECRUITING
Breast Cancer; Ductal Carcinoma; Estrogen-receptor-positive Breast Cancer; Atypical Lobular Hyperplasia; BRCA2 Mutation; CHEK2 Gene Mutation; Ataxia Telangiectasia Mutated Gene Mutation
Dana-Farber Cancer Institute
 2026-09-09 PHASE2
NCT05941520 RECRUITING
Breast Atypical Hyperplasia; Breast Carcinoma; Breast Ductal Carcinoma In Situ; Breast Lobular Carcinoma In Situ
National Cancer Institute (NCI)
 2024-10-10 PHASE2
NCT05774951 RECRUITING
Breast Cancer, Early Breast Cancer
AstraZeneca
 2023-03-31 PHASE3
NCT05472792 RECRUITING
Breast Cancer; Quality of Life
UNC Lineberger Comprehensive Cancer Center
 2022-05-17 PHASE2
NCT05501704 RECRUITING
Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma
Jose Pablo Leone
 2023-10-11 PHASE2
NCT06179303 RECRUITING
Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable HER2-Negative Breast Carcinoma; Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma
University of Washington
 2024-07-22 PHASE2
NCT06914674 RECRUITING
Pancreatic Neoplasms
Fudan University
 2025-03-20 PHASE2
NCT02476786 RECRUITING
Breast Cancer; Cancer of Breast; Breast Neoplasms; Cancer of the Breast
Washington University School of Medicine
 2017-01-17 PHASE2
NCT06364267 RECRUITING
Breast Cancer
Andrea DeCensi
 2025-10-01 PHASE2
NCT06195306 RECRUITING
Breast Atypical Hyperplasia; Breast Carcinoma; Breast Ductal Carcinoma In Situ; Breast Lobular Carcinoma In Situ
National Cancer Institute (NCI)
 2025-07-28 PHASE2
NCT05780567 ACTIVE_NOT_RECRUITING
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 2023-03-30 PHASE3
NCT05982093 RECRUITING
Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Premenopausal Breast Cancer
SOLTI Breast Cancer Research Group
 2023-02-03 PHASE2
NCT04174352 RECRUITING
ERα+ Breast Cancer; ESR1 Gene Mutation
University of Wisconsin, Madison
 2020-10-20 EARLY_PHASE1
NCT04765098 RECRUITING
Glioblastoma Multiforme
AHS Cancer Control Alberta
 2022-01-28 PHASE2
NCT03707340 ACTIVE_NOT_RECRUITING
Breast Cancer; Hyposexual Desire Disorder
Memorial Sloan Kettering Cancer Center
 2018-09-14 PHASE2
NCT06440967 ACTIVE_NOT_RECRUITING
Hot Flashes
Astellas Pharma Global Development, Inc.
 2024-07-31 PHASE3
NCT07616973 ACTIVE_NOT_RECRUITING
Infertility Drugs; Infertility Involuntary
Sana'a University
 2023-05-01 PHASE3
NCT03917082 ACTIVE_NOT_RECRUITING
Breast Cancer Female; Hormone Receptor Positive Tumor
British Columbia Cancer Agency
 2019-09-23 PHASE2
NCT04906395 ACTIVE_NOT_RECRUITING
Breast Cancer
Tolmar Inc.
 2021-07-01 PHASE3
NCT07289035 NOT_YET_RECRUITING
Cystic Fibrosis - Complete
Azienda Ospedaliera Universitaria Integrata Verona
 2026-01-15 PHASE2
NCT06630325 TERMINATED
Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8
OHSU Knight Cancer Institute
 2025-06-24 PHASE2
NCT06355401 NOT_YET_RECRUITING
Diffuse Large B Cell Lymphoma
Sohag University
 2024-04 PHASE2; PHASE3
NCT05156892 ACTIVE_NOT_RECRUITING
Ovarian Cancer
Anthony Joshua, FRACP
 2022-09-04 PHASE1
NCT04046159 UNKNOWN
Breast Ductal Carcinoma in Situ
National Taiwan University Hospital
 2019-04-30 PHASE3
NCT05150652 COMPLETED
Breast Cancer; HER2-negative Breast Cancer; Node-negative Breast Cancer; Breast Carcinoma
Irada Ibrahim-zada
 2022-02-18 PHASE2
NCT03351062 UNKNOWN
Breast Cancer Female
Chinese Anti-Cancer Association
 2017-11 PHASE3
NCT06033092 ACTIVE_NOT_RECRUITING
BRCA Mutation; PALB2 Gene Mutation; Ductal Carcinoma in Situ; Lobular Carcinoma in Situ; ATM Gene Mutation; CHEK2 Gene Mutation; CDH1 Gene Mutation; RAD51C Gene Mutation; RAD51D Gene Mutation
European Institute of Oncology
 2024-06-21 PHASE2
NCT04961632 UNKNOWN
Breast Cancer
National Cancer Centre, Singapore
 2020-12-23 PHASE1
NCT03423199 UNKNOWN
Breast Neoplasms
National Cancer Center, Japan
 2018-02-09 PHASE3
NCT05306340 ACTIVE_NOT_RECRUITING
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Genentech, Inc.
 2022-08-03 PHASE3
NCT07145827 COMPLETED
Breast Cancer; Endometrial Hyperplasia and Endometrial Cancers
Uruk University
 2024-01-02
NCT02062489 UNKNOWN
Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
 2014-05 PHASE3
NCT05463601 ACTIVE_NOT_RECRUITING
Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
 2022-08-01 PHASE2
NCT05659563 COMPLETED
Breast Cancer; Breast Cancer, Early-Onset
MedSIR
 2023-07-20 PHASE2
NCT06001762 ACTIVE_NOT_RECRUITING
Breast Cancer; Early-stage Breast Cancer; High Risk Breast Carcinoma
Dana-Farber Cancer Institute
 2023-10-05 PHASE2
NCT04997941 ACTIVE_NOT_RECRUITING
Premenopausal Breast Cancer; Hormone Receptor-positive Breast Cancer
Seoul National University Hospital
 2021-10-21 PHASE2
NCT03664895 UNKNOWN
Breast Cancer Invasive
Seoul National University Hospital
 2018-09-03 PHASE3
NCT00412022 UNKNOWN
Breast Cancer
National Cancer Institute, Naples
 2004-03 PHASE3
NCT04570956 TERMINATED
Breast Atypical Hyperplasia; Breast Lobular Carcinoma in Situ; Breast Atypical Lobular Hyperplasia; Breast Carcinoma
Mayo Clinic
 2021-07-26 PHASE2
NCT03280563 COMPLETED
Breast Neoplasms
Hoffmann-La Roche
 2017-12-22 PHASE1; PHASE2
NCT03355157 COMPLETED
Metastatic Breast Cancer
GBG Forschungs GmbH
 2018-03-01 PHASE4
NCT04666961 RECRUITING
Ductal Carcinoma in Situ; Extensive Disease; Mastectomy
Institut Cancerologie de l'Ouest
 2021-02-03 PHASE2
NCT05156606 TERMINATED
Male Breast Cancer
University Medical Center Groningen
 2022-11-10
NCT02206984 COMPLETED
Breast Cancer
Priscilla McAuliffe
 2015-09-30 PHASE2
NCT05669768 UNKNOWN
Ovarian Cancer
Sun Yat-sen University
 2023-01-01 PHASE2
NCT06154590 Not yet recruiting
Metastatic Breast Cancer|Tumor|Muscle Neoplasms|Chronic Pain
DR. DIANE CHISESI NFS. MD. PHD.|IRB|Paradyne Networks A Foundation
 2024-07 --
NCT04272801 ACTIVE_NOT_RECRUITING
Breast Cancer Female
Shayna Showalter, MD
 2020-04-07 PHASE2
NCT05101564 COMPLETED
Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast Cancer
Jennifer Lee Caswell-Jin
 2023-03-20 PHASE2
NCT04933240 WITHDRAWN
Vaginal Bleeding
Virginia Commonwealth University
 2022-05 PHASE4
NCT04915846 TERMINATED
X Linked Myotubular Myopathy
James Dowling
 2020-12-18 PHASE1; PHASE2
NCT05501158 UNKNOWN
Breast Cancer
Nalagenetics Pte Ltd
 2021-01-01
NCT03906669 UNKNOWN
Early-stage Breast Cancer; Hormone Receptor Positive Tumor
St Vincent's Hospital
 2018-03-20 PHASE2
NCT02097459 UNKNOWN
Breast Cancer
Peking Union Medical College Hospital
 2014-03 PHASE3
NCT05525481 UNKNOWN
ER+ Breast Cancer
Erasmus Medical Center
 2022-11-01 PHASE4
NCT03554044 COMPLETED
Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast Carcinoma
University of California, San Francisco
 2020-02-05 PHASE1
NCT02914158 UNKNOWN
Breast Cancer
First Affiliated Hospital, Sun Yat-Sen University
 2016-03-30 PHASE3
NCT03161353 ACTIVE_NOT_RECRUITING
Breast Cancer
MedSIR
 2017-06-26 PHASE2
NCT03137368 UNKNOWN
CYP2D6 Polymorphism
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
 2018-08-09 PHASE3
NCT04200066 WITHDRAWN
Glioblastoma; Brain Tumor
University of Rochester
 2022-06-01 PHASE1
NCT02668666 COMPLETED
Hormone Receptor Positive Malignant Neoplasm of Breast; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Estrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Metastatic Breast Cancer
Oana Danciu, MD
 2017-02-01 PHASE2
NCT04190056 TERMINATED
Anatomic Stage IV Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8
University of California, San Francisco
 2021-03-11 PHASE2
NCT03528902 COMPLETED
Hypertension; Pulmonary Arterial Hypertension; Familial Primary Pulmonary Hypertension; Primary Pulmonary Hypertension; Lung Diseases; Tamoxifen; Estrogen Receptor Antagonist; Hormone Antagonists; Estrogens
Vanderbilt University Medical Center
 2018-10-01 PHASE2
NCT03870399 COMPLETED
Neuroendocrine Tumors; Progesterone Receptor Positive Tumor; Estrogen Receptor Positive Tumor
AC Camargo Cancer Center
 2019-03-13 PHASE2
NCT04433494 UNKNOWN
Breast Cancer; Solid Tumor
TYK Medicines, Inc
 2020-12-07 PHASE1
NCT04038489 WITHDRAWN
Breast Cancer; Estrogen Receptor-positive Breast Cancer
University of Virginia
 2019-10-18 PHASE2
NCT03879577 ACTIVE_NOT_RECRUITING
Breast Cancer; Breast Cancer Female; HER2-positive Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III
University of Chicago
 2019-11-25 PHASE2
NCT03238703 WITHDRAWN
HER2/Neu Negative; Invasive Breast Carcinoma; Postmenopausal; Stage 0 Breast Cancer; Stage IA Breast Cancer
Fred Hutchinson Cancer Center
 2018-09-01 PHASE4
NCT01272037 ACTIVE_NOT_RECRUITING
Breast Ductal Carcinoma In Situ; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma
National Cancer Institute (NCI)
 2011-02-28 PHASE3
NCT05133674 UNKNOWN
Breast Cancer; Breast Carcinoma; Breast Tumors; Cancer of Breast; Malignant Neoplasm of Breast
Karolinska University Hospital
 2022-04-04 PHASE2
NCT01357772 ACTIVE_NOT_RECRUITING
Carcinoma, Intraductal, Noninfiltrating; Recurrence, Local Neoplasm; Breast Neoplasms; Atypical Hyperplasia
Andrea DeCensi
 2008-11-12 PHASE3
NCT05378269 COMPLETED
Vulvar Atrophy
Daré Bioscience, Inc.
 2021-11-22 PHASE1; PHASE2
NCT01674140 ACTIVE_NOT_RECRUITING
Breast Cancer
SWOG Cancer Research Network
 2013-09-12 PHASE3
NCT04129216 COMPLETED
Breast Cancer
Johns Hopkins University
 2019-02-20 PHASE2
NCT03691493 COMPLETED
Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Bone; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8
Emory University
 2019-02-08 PHASE2
NCT05128773 TERMINATED
Breast Cancer
Sanofi
 2022-02-17 PHASE3
NCT05200663 UNKNOWN
Oligoasthenoteratozoospermia; Male Infertility
Sharif Medical Research Center
 2021-10-15 PHASE2
NCT02333370 COMPLETED
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Novartis Pharmaceuticals
 2015-02-04 PHASE1
NCT05156892 Recruiting
Ovarian Cancer
Anthony Joshua FRACP|Royal Prince Alfred Hospital Sydney Australia|Concord Hospital|Prince of Wales Hospital Sydney|St Vincent''s Hospital Sydney
 2022-09-04 Phase 1
NCT03879174 UNKNOWN
Breast Cancer Female
Mediclinic Middle East
 2019-08-01 PHASE2
NCT03354039 COMPLETED
Duchenne Muscular Dystrophy
University Hospital, Basel, Switzerland
 2018-06-12 PHASE3
NCT04300790 COMPLETED
Breast Cancer
MedSIR
 2020-10-23 PHASE2
NCT00738777 SUSPENDED
Breast Cancer
The Netherlands Cancer Institute
 2008-07 PHASE2
NCT04200066 Withdrawn
Glioblastoma|Brain Tumor
University of Rochester
 2022-06-01 Phase 1
NCT02285179 COMPLETED
Breast Cancer
The Netherlands Cancer Institute
 2014-11 PHASE1; PHASE2
NCT02913430 COMPLETED
Metastatic Breast Cancer
Shannon Puhalla
 2018-04-24 EARLY_PHASE1
NCT05133674 Unknown status
Breast Cancer|Breast Carcinoma|Breast Tumors|Cancer of Breast|Malignant Neoplasm of Breast
Karolinska University Hospital
 2022-04-04 Phase 2
NCT00301457 COMPLETED
Breast Cancer
Maastricht University Medical Center
 2006-06 PHASE3
NCT04059484 TERMINATED
Breast Cancer Metastatic
Sanofi
 2019-10-22 PHASE2
NCT02764541 ACTIVE_NOT_RECRUITING
Breast Cancer
Dana-Farber Cancer Institute
 2016-05-24 PHASE2
NCT03063619 COMPLETED
Mammographically Dense Breast
M.D. Anderson Cancer Center
 2018-01-30 PHASE2
NCT04504331 TERMINATED
Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer
Jennifer Lee Caswell-Jin
 2020-10-13 PHASE1
NCT04389580 UNKNOWN
COVID-19
Kafrelsheikh University
 2021-09 PHASE2
NCT05016349 UNKNOWN
Breast Cancer Female
Mahmoud Ramadan mohamed Elkazzaz
 2021-08 PHASE3
NCT02584465 COMPLETED
Ovarian Carcinoma
ARCAGY/ GINECO GROUP
 2015-08-28 PHASE2
NCT02603679 ACTIVE_NOT_RECRUITING
Early-Stage Breast Carcinoma; Estrogen Receptor Positive Tumor
Thomas Hatschek
 2015-02 PHASE2
NCT03931928 COMPLETED
Breast Cancer; DCIS
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
 2019-09-10 PHASE2
NCT04312347 COMPLETED
ER+ Breast Cancer
Nalagenetics Pte Ltd
 2019-09-06
NCT02993159 COMPLETED
Ductal Breast Carcinoma In Situ; Estrogen Receptor Positive
Northwestern University
 2017-05-31 PHASE2
NCT02057133 ACTIVE_NOT_RECRUITING
Breast Neoplasms
Eli Lilly and Company
 2014-03-10 PHASE1
NCT02384239 COMPLETED
Metastatic Breast Cancer; Hormone Receptor Positive
University of California, San Francisco
 2015-10-19 PHASE2
NCT02269670 TERMINATED
Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Emory University
 2014-11-25 PHASE2
NCT04292886 UNKNOWN
Thin Endometrium
Nanjing University
 2019-10-01
NCT04568096 UNKNOWN
the Lung Complication of COVID-19
Kafrelsheikh University
 2020-11 PHASE2
NCT01124695 COMPLETED
Breast Cancer; Stage IV Breast Cancer
ECOG-ACRIN Cancer Research Group
 2011-01-07 PHASE2
NCT02311933 ACTIVE_NOT_RECRUITING
Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7
National Cancer Institute (NCI)
 2015-05-28 PHASE2
NCT02801786 UNKNOWN
Pain; Discomfort
Universidade Federal de Goias
 2018-11 PHASE2; PHASE3
NCT02835079 COMPLETED
Duchenne Muscular Dystrophy
Hadassah Medical Organization
 2016-11 PHASE1
NCT00538330 UNKNOWN
Breast Cancer
King Faisal Specialist Hospital & Research Center
 2007-09
NCT03518138 COMPLETED
Vasomotor Symptoms (VMS)
Que Oncology
 2018-10-24 PHASE2
NCT03272477 COMPLETED
Breast Neoplasms
Palleos Healthcare GmbH
 2017-10-05 PHASE2
NCT00541086 UNKNOWN
Breast Cancer
Gruppo Italiano Mammella (GIM)
 2007-03 PHASE3
NCT02624973 ACTIVE_NOT_RECRUITING
Breast Cancer
Haukeland University Hospital
 2016-04-15 PHASE2
NCT02936206 TERMINATED
Breast Cancer
Icahn School of Medicine at Mount Sinai
 2016-10 PHASE1
NCT02132000 UNKNOWN
Breast Cancer Patients in Premenopausal; Estrogen and/or Progesterone Receptor Positive
Fengxi Su
 2014-04 PHASE2; PHASE3
NCT00433589 COMPLETED
Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
 2007-02 PHASE3
NCT03024580 UNKNOWN
Breast Neoplasm
Instituto Nacional de Cancer, Brazil
 2017-03-06 PHASE2
NCT03219476 COMPLETED
Breast Cancer; Invasive Breast Cancer
Medical College of Wisconsin
 2017-02-05 PHASE2
NCT01758146 UNKNOWN
Breast Cancer
Post Graduate Institute of Medical Education and Research, Chandigarh
 2012-01 PHASE3
NCT03373708 UNKNOWN
Breast Cancer; Chemotherapy; Endocrine Breast Diseases
Zhiyong Yu
 2017-12-20 PHASE2; PHASE3
NCT02517593 COMPLETED
Breast Cancer
Mayo Clinic
 2016-03 PHASE1; PHASE2
NCT03060304 UNKNOWN
Endometrium
Sun Yat-sen University
 2017-03 PHASE4
NCT03346200 COMPLETED
Risk Reduction; Mammographic Density Reduction
Per Hall
 2016-11 PHASE2
NCT02166944 COMPLETED
Amyotrophic Lateral Sclerosis; ALS Functional Ration Scale; TAR-DNA-binding Protein-43; Tamoxifen; mTOR
Taipei Medical University Shuang Ho Hospital
 2014-04 PHASE1; PHASE2
NCT02395627 TERMINATED
Breast Neoplasms
University of California, San Francisco
 2015-05-04 PHASE2
NCT02903121 COMPLETED
Bleeding; Implants; Breakthrough Bleeding
Oregon Health and Science University
 2017-01-20 PHASE4
NCT02101788 COMPLETED
Borderline Ovarian Serous Tumor; Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Low Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)
 2014-04-11 PHASE2; PHASE3
NCT03058939 WITHDRAWN
Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III
University of Chicago
 2018-11 PHASE2
NCT02819921 TERMINATED
Hot Flashes; Breast Neoplasms
Seoul National University Hospital
 2017-11-10 PHASE4
NCT00866554 COMPLETED
Prostate Cancer; Erectile Dysfunction; Lower Urinary Tract Symptoms
CHU de Quebec-Universite Laval
 2009-03 PHASE2
NCT03045653 COMPLETED
Breast Cancer Metastatic
Sun Yat-sen University
 2017-09-01 PHASE2
NCT02988986 COMPLETED
Estrogen Receptor Positive Breast Cancer
The Methodist Hospital Research Institute
 2017-04-24 PHASE2
NCT02592083 ACTIVE_NOT_RECRUITING
Early-Stage Breast Carcinoma; Hormone Receptor Positive Tumor
Thomas Hatschek
 2015-10 PHASE2
NCT02291913 COMPLETED
Breast Cancer
SCRI Development Innovations, LLC
 2014-12-18 PHASE2
NCT03199963 TERMINATED
Mammographic Breast Density
BHR Pharma, LLC
 2017-08-21 PHASE3
NCT02970682 COMPLETED
Breast Neoplasm
Evgen Pharma
 2016-10 PHASE2
NCT01196936 ACTIVE_NOT_RECRUITING
Breast Cancer
University of Alabama at Birmingham
 2010-09 PHASE2
NCT03382834 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2018-04-26 PHASE2
NCT03715413 COMPLETED
Breast Fibroadenoma
Mansoura University
 2018-08-15 PHASE2
NCT01579734 UNKNOWN
Breast Cancer
European Institute of Oncology
 2002-03 PHASE3
NCT02995772 COMPLETED
Breast Cancer
Dharmais National Cancer Center Hospital
 2011-11 PHASE3
NCT02344550 COMPLETED
Metastatic Breast Cancer
Asan Medical Center
 2014-01 PHASE2
NCT02630693 COMPLETED
Breast Cancer
Canadian Cancer Trials Group
 2016-04-08 PHASE2
NCT01971515 COMPLETED
Solid Tumor
EMD Serono
 2013-12-13 PHASE1
NCT02513849 UNKNOWN
Cancer; Gastrointestinal Neoplasms
University of Nottingham
 2015-12 PHASE1
NCT02488603 UNKNOWN
Breast Cancer
National Cancer Center, Korea
 2015-08
NCT03211572 UNKNOWN
Breast Cancer
Ottawa Hospital Research Institute
 2017-08 PHASE2
NCT02344940 COMPLETED
Breast Cancer
Shanghai Jiao Tong University School of Medicine
 2014-12 PHASE4
NCT03112031 COMPLETED
Meningitis Streptococcal; Hiv; Meningitis; Meningoencephalitis
Oxford University Clinical Research Unit, Vietnam
 2017-10-10 PHASE2
NCT02058381 COMPLETED
Pre-menopausal Breast Cancer; PI3K Pathway Inhibition
Novartis Pharmaceuticals
 2014-05-06 PHASE1
NCT02747004 ACTIVE_NOT_RECRUITING
Metastatic Breast Cancer
Eli Lilly and Company
 2016-09-14 PHASE2
NCT01266213 UNKNOWN
Metastatic Breast Cancer; Estrogen Receptor Positive Tumor; Breast Cancer Nos Premenopausal
Samsung Medical Center
 2010-12 PHASE2
NCT01638247 COMPLETED
Male Breast Cancer
GBG Forschungs GmbH
 2012-08 PHASE3
NCT02690870 UNKNOWN
Infertility
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
 2017-01 PHASE4
NCT01503905 UNKNOWN
Breast Cancer Nos Premenopausal
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
 2011-12
NCT00310180 ACTIVE_NOT_RECRUITING
Breast Adenocarcinoma; Hormone Receptor Positive; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIB Breast Cancer AJCC v7
National Cancer Institute (NCI)
 2006-04-07 PHASE3
NCT02979301 COMPLETED
High Background Uptake on MBI
Mayo Clinic
 2017-03-01
NCT02824224 COMPLETED
Menorrhagia; Metrorrhagia; Medicated Intrauterine Devices
Oregon Health and Science University
 2016-09-06 PHASE4
NCT02228681 COMPLETED
Advanced, Persistent, or Recurrent Endometrial Cancer
GOG Foundation
 2015-05-21 PHASE2
NCT01127295 COMPLETED
Hormono-depending Adjuvant Breast Cancer
Institut Claudius Regaud
 2010-06-17 PHASE4
NCT02404844 COMPLETED
Breast Cancer
University Hospital, Essen
 2014-12 PHASE2
NCT02197897 COMPLETED
Bladder Cancer
Baylor College of Medicine
 2015-04-01 PHASE2
NCT02467686 UNKNOWN
Sexuality
Irmandade da Santa Casa de Misericordia de Sao Paulo
 2014-01 PHASE4
NCT00077168 UNKNOWN
Breast Cancer
Institute of Cancer Research, United Kingdom
 2004-04 PHASE2
NCT02278120 COMPLETED
Advanced Metastatic Breast Cancer
Novartis Pharmaceuticals
 2014-11-20 PHASE3
NCT04479098 COMPLETED
Breast Neoplasm Female
Federal University of Uberlandia
 2016-07-01
NCT02890082 ACTIVE_NOT_RECRUITING
Breast Cancer
Institut Cancerologie de l'Ouest
 2014-02 PHASE2
NCT02586675 COMPLETED
Breast Cancer; Breast Cancer - Female; Breast Cancer - Male
H. Lee Moffitt Cancer Center and Research Institute
 2016-02-23 PHASE1
NCT01234532 TERMINATED
Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Triple-negative Breast Cancer
University of Maryland, Baltimore
 2010-10 PHASE2
NCT02322853 TERMINATED
Postmenopausal; Metastatic Breast Cancer
Centre Francois Baclesse
 2015-01 PHASE2
NCT00729586 COMPLETED
Endometrial Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC1 Uterine Corpus Cancer; Stage IIIC2 Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer
National Cancer Institute (NCI)
 2008-09 PHASE2
NCT02482740 UNKNOWN
Uterine Cervical Neoplasms
Buddhist Tzu Chi General Hospital
 2015-05 PHASE2
NCT02313051 UNKNOWN
Metastatic Breast Cancer
Chinese Academy of Medical Sciences
 2014-12 PHASE2
NCT01614210 COMPLETED
Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer
University of Utah
 2012-08 PHASE2
NCT01771458 COMPLETED
Reccurent/Metastatic Solid Tumor Disease
Institut Curie
 2012-10 PHASE2
NCT01220076 COMPLETED
Non Metastatic Breast Cancer
Institut Cancerologie de l'Ouest
 2009-09 PHASE2
NCT00382070 UNKNOWN
Breast Cancer
NSABP Foundation Inc
 2006-08 PHASE3
NCT02089386 TERMINATED
Barrett Metaplasia
Washington University School of Medicine
 2014-07-09 EARLY_PHASE1
NCT02479256 COMPLETED
PCOS
Ain Shams University
 2015-06 PHASE4
NCT01622361 UNKNOWN
Breast Cancer
Asan Medical Center
 2012-06 PHASE3
NCT04079517 COMPLETED
Breast Cancer; Mammographic Density
Karolinska Institutet
 2015-03 PHASE1; PHASE2
NCT01612871 COMPLETED
Breast Cancer
Institut Claudius Regaud
 2012-06-27 PHASE4
NCT00754845 COMPLETED
Breast Cancer
Canadian Cancer Trials Group
 2004-11-23 PHASE3
NCT00912548 UNKNOWN
Breast Cancer
Korean Breast Cancer Study Group
 2009-05 PHASE3
NCT00072462 COMPLETED
Breast Cancer
Queen Mary University of London
 2003-09 PHASE3
NCT01027416 COMPLETED
Breast Cancer
Roswell Park Cancer Institute
 2009-12-14
NCT02070692 COMPLETED
Menstruation Disturbances
Oregon Health and Science University
 2014-02 PHASE4
NCT01352091 UNKNOWN
Breast Cancer
Fudan University
 2008-05 PHASE3
NCT01293032 COMPLETED
Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer
Virginia Commonwealth University
 2011-04
NCT02093351 COMPLETED
Solid Tumours
AstraZeneca
 2014-09-01 PHASE1
NCT00053898 COMPLETED
Breast Cancer
NSABP Foundation Inc
 2003-01 PHASE3
NCT00659373 COMPLETED
Breast Cancer; Fatigue; Sleep Disorders
ETOP IBCSG Partners Foundation
 2007-12 PHASE3
NCT01685255 TERMINATED
Ovarian Cancer; Genitourinary (GU) Tumors
Incyte Corporation
 2012-08 PHASE2
NCT01391689 COMPLETED
Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer
University of Arizona
 2011-02
NCT02806544 COMPLETED
Breast Cancer; Breast Neoplasms
Vanderbilt University
 2013-01 PHASE2
NCT02866955 COMPLETED
Breast Cancer
Institut de Cancérologie de Lorraine
 2011-06-15 PHASE2
NCT00999921 COMPLETED
Benign Breast Disease; Fibrocystic Disease of Breast; Fibroadenoma; Mastalgia
Medical College and Hospital Kolkata
 2008-01 PHASE4
NCT04080297 COMPLETED
Vasomotor Symptoms (VMS)
Que Oncology
 2014-01-10 PHASE1
NCT00601900 COMPLETED
Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v6; Stage IV Breast Cancer AJCC v6 and v7
National Cancer Institute (NCI)
 2008-09-24 PHASE3
NCT00066690 COMPLETED
Estrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer
ETOP IBCSG Partners Foundation
 2003-12-17 PHASE3
NCT00293540 COMPLETED
Breast Cancer
International Breast Cancer Research Foundation
 2006-02 PHASE3
NCT01194908 TERMINATED
Breast Cancer; Breast Tumors; Breast Neoplasms
Emory University
 2010-07 PHASE1; PHASE2
NCT00963209 UNKNOWN
Breast Cancer
Centre Hospitalier Universitaire Vaudois
 2009-06 PHASE3
NCT01821066 COMPLETED
Healthy
Pfizer
 2013-04 PHASE1
NCT01553903 COMPLETED
Breast Cancer
Institut Claudius Regaud
 2011-12 PHASE4
NCT00108069 COMPLETED
Glioma
National Cancer Institute (NCI)
 2005-04 PHASE2
NCT00290654 TERMINATED
Breast Cancer
Masonic Cancer Center, University of Minnesota
 2002-12 PHASE2
NCT01393990 COMPLETED
Advanced Cancer
Eli Lilly and Company
 2008-09-04 PHASE1
NCT01831076 COMPLETED
Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer
University of Colorado, Denver
 2002-04 PHASE2
NCT00847366 COMPLETED
Non Small Cell Lung Cancer; Solid Tumors; Metastatic Breast Cancer; Sarcomas
AEterna Zentaris
 2008-05
NCT01257581 COMPLETED
Amyotrophic Lateral Sclerosis
Nazem Atassi
 2011-03 PHASE2
NCT00489944 UNKNOWN
Intraocular Melanoma
San Diego Pacific Oncology & Hematology Associates
 2007-05 PHASE2
NCT01231659 COMPLETED
Postmenopausal Women; Locally Advanced Metastatic Breast Cancer; Metastatic Breast Cancer
Novartis Pharmaceuticals
 2011-08-09 PHASE2
NCT01075802 COMPLETED
Breast Cancer; CYP2D6 Polymorphism
Western Sydney Local Health District
 2010-03
NCT00684216 TERMINATED
Breast Cancer
The Netherlands Cancer Institute
 2008-04 PHASE2; PHASE3
NCT00893061 COMPLETED
Breast Cancer
Centre Oscar Lambret
 2009-03-16 PHASE3
NCT00728949 COMPLETED
Metastatic Breast Cancer
Eli Lilly and Company
 2008-08 PHASE2
NCT00047099 COMPLETED
Breast Cancer
Ludwig-Maximilians - University of Munich
 2001-08 PHASE3
NCT00756717 COMPLETED
Breast Cancer
Loyola University
 2008-02-14 PHASE4
NCT00492505 UNKNOWN
Melanoma (Skin)
San Diego Pacific Oncology & Hematology Associates
 2007-04 PHASE2
NCT00710970 COMPLETED
Urinary Bladder Neoplasms
Seth Lerner
 2007-01 PHASE2
NCT00896155 UNKNOWN
Pulmonary Fibrosis; Breast Cancer
Tata Memorial Hospital
 2008-12 PHASE3
NCT00201851 COMPLETED
Breast Cancer
International Breast Cancer Research Foundation
 2004-01 PHASE3
NCT00537771 COMPLETED
Breast Cancer
AstraZeneca
 2007-09 PHASE4
NCT01194427 TERMINATED
Stage I Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer; Invasive Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
 2011-03 PHASE2
NCT00952731 COMPLETED
Ductal Breast Carcinoma in Situ; Estrogen Receptor-positive Breast Cancer
Northwestern University
 2009-12 PHASE2
NCT00002784 COMPLETED
Breast Cancer
ETOP IBCSG Partners Foundation
 1996-06 PHASE3
NCT00118157 COMPLETED
Estrogen Receptor Positive; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
National Cancer Institute (NCI)
 2005-05 PHASE2
NCT01298713 COMPLETED
Breast Neoplasms; mTor Protein
ARCAGY/ GINECO GROUP
 2008-03 PHASE2
NCT00827307 COMPLETED
Mammography; Estrogen; Lipemia; Endometrium; Ultrasonography
Zhejiang Cancer Hospital
 2008-06
NCT01192308 COMPLETED
Breast Cancer
Radboud University Medical Center
 2010-07 PHASE1
NCT00365599 COMPLETED
Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
 2006-02 PHASE2
NCT00066703 COMPLETED
Breast Cancer
ETOP IBCSG Partners Foundation
 2003-11-03 PHASE3
NCT00171704 COMPLETED
Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women
Novartis Pharmaceuticals
 2005-04 PHASE3
NCT00041080 COMPLETED
Fallopian Tube Cancer; Primary Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer; Stage III Ovarian Epithelial Cancer; Stage IV Ovarian Epithelial Cancer
National Cancer Institute (NCI)
 2003-02 PHASE3
NCT00629278 UNKNOWN
Breast Cancer
Azienda Ospedaliero-Universitaria di Modena
 2007-12 PHASE3
NCT01189500 COMPLETED
Pharmacokinetics
Pfizer
 2010-08 PHASE4
NCT00949598 COMPLETED
Breast Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
 2008-12 PHASE3
NCT00764322 COMPLETED
Breast Cancer; Menopausal Symptoms
UNC Lineberger Comprehensive Cancer Center
 2008-06-18 PHASE2
NCT00993642 WITHDRAWN
Breast Cancer
Tulane University Health Sciences Center
 2009-09 EARLY_PHASE1
NCT00002529 COMPLETED
Breast Cancer
ETOP IBCSG Partners Foundation
 1993-05 PHASE3
NCT00194779 COMPLETED
Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer
University of Washington
 2003-10 PHASE2
NCT00068419 COMPLETED
Desmoid Tumor
Children's Oncology Group
 2004-02 PHASE2
NCT00003042 COMPLETED
Breast Cancer
City of Hope Medical Center
 1997-05-30 PHASE2
NCT00003199 COMPLETED
Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Inflammatory Breast Cancer; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage IIIB Breast Cancer; Stage IV Breast Cancer
Fred Hutchinson Cancer Center
 1997-11 PHASE2
NCT00605267 COMPLETED
Breast Cancer
AstraZeneca
 2007-10 PHASE3
NCT00119262 COMPLETED
Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer
National Cancer Institute (NCI)
 2005-10 PHASE2
NCT00290745 COMPLETED
Breast Cancer
University of California, San Francisco
 2002-02-19 PHASE1; PHASE2
NCT00499083 COMPLETED
Breast Cancer
University of Nebraska
 2006-05-01 PHASE2
NCT00492687 UNKNOWN
Brain and Central Nervous System Tumors
San Diego Pacific Oncology & Hematology Associates
 2006-12 PHASE2
NCT00291759 COMPLETED
Breast Cancer
AstraZeneca
 1996-01 PHASE3
NCT00424164 COMPLETED
Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
 2006-11 PHASE1
NCT00749138 COMPLETED
Chronic Hepatitis C
Bader, Ted, M.D.
 2008-11 PHASE1
NCT00004205 COMPLETED
Breast Cancer
ETOP IBCSG Partners Foundation
 1998-03 PHASE3
NCT00305838 UNKNOWN
Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Mount Vernon Cancer Centre at Mount Vernon Hospital
 2004-03 PHASE2
NCT00279448 COMPLETED
Breast Neoplasms
Pfizer
 2002-01 PHASE3
NCT00036270 COMPLETED
Breast Neoplasms
Pfizer
 2001-08 PHASE3
NCT00967824 COMPLETED
Breast Cancer
University of Michigan Rogel Cancer Center
 2005-10 PHASE1; PHASE2
NCT00183963 TERMINATED
Breast Carcinoma
University of Southern California
 2006-08 PHASE2
NCT00152178 COMPLETED
Breast Cancer
Taiho Pharmaceutical Co., Ltd.
 1996-07 PHASE3
NCT00295646 COMPLETED
Breast Cancer
Austrian Breast & Colorectal Cancer Study Group
 1999-06 PHASE3
NCT00038103 COMPLETED
Breast Neoplasms
Pfizer
 2002-01 PHASE2
NCT00687102 COMPLETED
Cognition; Aging
Wake Forest University
 2001-10 PHASE3
NCT02728622 COMPLETED
Ovarian Cancer; Peritoneal Cancer; Cancer of the Fallopian Tube
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
 2002-03 PHASE3
NCT00005908 COMPLETED
Breast Cancer; Breast Neoplasm
National Cancer Institute (NCI)
 2000-06 PHASE2
NCT00002864 COMPLETED
Breast Cancer
NCIC Clinical Trials Group
 1996-09-24 PHASE3
NCT00206544 COMPLETED
Bipolar Disorder; Mania; Schizoaffective Disorder
The Alfred
 2004-01 PHASE2
NCT00233610 COMPLETED
Prostate Cancer
AstraZeneca
 2003-12 PHASE3
NCT00541138 COMPLETED
Brain and Central Nervous System Tumors; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
City of Hope Medical Center
 2003-05 PHASE2
NCT00004125 COMPLETED
Breast Cancer
Eastern Cooperative Oncology Group
 1999-11-16 PHASE3
NCT00649090 COMPLETED
Breast Neoplasms
Pfizer
 2005-03 PHASE4
NCT00096369 TERMINATED
Breast Cancer
University of Texas Southwestern Medical Center
 2000-02 PHASE2
NCT00002542 COMPLETED
Breast Cancer
NCIC Clinical Trials Group
 1993-07-20 PHASE3
NCT00241449 COMPLETED
Breast Cancer; Metastasis
AstraZeneca
 1998-11 PHASE3
NCT00107263 COMPLETED
Breast Cancer; Osteoporosis
Alliance for Clinical Trials in Oncology
 2005-01 PHASE3
NCT00003992 COMPLETED
Breast Cancer
National Cancer Institute (NCI)
 1999-08 PHASE2
NCT00002920 COMPLETED
Breast Cancer; Endometrial Cancer
SWOG Cancer Research Network
 1997-03 PHASE3
NCT00066807 TERMINATED
Breast Cancer
ETOP IBCSG Partners Foundation
 2003-08 PHASE3
NCT00040014 TERMINATED
Breast Neoplasms
Pfizer
 2002-06 PHASE2
NCT00229697 COMPLETED
Breast Neoplasms
AstraZeneca
 2003-10 PHASE2
NCT01157026 COMPLETED
Breast Cancer
Malaysia Palm Oil Board
 2001-11
NCT00206492 TERMINATED
Breast Cancer
Baylor Breast Care Center
 2003-07 PHASE2
NCT00007904 COMPLETED
Breast Cancer
Case Comprehensive Cancer Center
 2000-07 PHASE2
NCT00532454 TERMINATED
Breast Cancer; Metastatic Disease
National Cancer Center, Korea
 2006-06 PHASE2
NCT00919399 COMPLETED
Breast Neoplasms
Institut Claudius Regaud
 2002-01 PHASE2
NCT00031720 COMPLETED
Breast Cancer; Hot Flashes; Hot Flushes
Alliance for Clinical Trials in Oncology
 2002-03 PHASE2
NCT00003906 COMPLETED
Breast Cancer
NSABP Foundation Inc
 1999-05 PHASE3
NCT00929591 COMPLETED
Breast Cancer
SWOG Cancer Research Network
 1989-05 PHASE3
NCT00637871 COMPLETED
Gynaecomastia; Prostate Cancer
AstraZeneca
 2002-11 PHASE2
NCT00005970 COMPLETED
Breast Adenocarcinoma; HER2 Positive Breast Carcinoma; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7
National Cancer Institute (NCI)
 2000-05-19 PHASE3
NCT00253539 COMPLETED
Breast Cancer; Hereditary Breast/Ovarian Cancer (brca1, brca2)
The Cleveland Clinic
 2002-01 PHASE2
NCT00080743 COMPLETED
Breast Cancer
Dartmouth-Hitchcock Medical Center
 2004-01 PHASE2
NCT00016276 TERMINATED
Cardiac Toxicity; Inflammatory Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IV Breast Cancer
National Cancer Institute (NCI)
 2001-05 PHASE3
NCT00784940 COMPLETED
Bone Density
AstraZeneca
 1998-06 PHASE3
NCT00309478 COMPLETED
Early-stage Breast Cancer
Austrian Breast & Colorectal Cancer Study Group
 1990-12 PHASE3
NCT00053911 TERMINATED
Breast Cancer
UNICANCER
 2002-11 PHASE3
NCT00165308 COMPLETED
Hodgkin's Disease; Breast Cancer
Dana-Farber Cancer Institute
 2001-04
NCT00272714 COMPLETED
Cyclic Breast Pain, Cyclic Mastalgia
ASCEND Therapeutics
 2003-03 PHASE2
NCT00003857 COMPLETED
Breast Cancer
Radiation Therapy Oncology Group
 1999-12 PHASE3
NCT00002646 COMPLETED
Breast Cancer
Eastern Cooperative Oncology Group
 1995-10 PHASE3
NCT00002772 TERMINATED
Breast Cancer
SWOG Cancer Research Network
 1996-07 PHASE3
NCT00009997 COMPLETED
Breast Cancer
NYU Langone Health
 1999-03 PHASE1
NCT00016341 TERMINATED
Endometrial Cancer
Gynecologic Oncology Group
 2001-05 PHASE3
NCT00006388 COMPLETED
Brain and Central Nervous System Tumors
Radiation Therapy Oncology Group
 2000-12 PHASE2
NCT00016432 COMPLETED
Breast Cancer
NSABP Foundation Inc
 2001-05 PHASE3
NCT00003140 COMPLETED
Breast Cancer
NCIC Clinical Trials Group
 1998-08-24 PHASE3
NCT00038467 COMPLETED
Breast Neoplasms
Pfizer
 1998-02 PHASE3
NCT00003972 COMPLETED
Breast Cancer
Fred Hutchinson Cancer Center
 1998-07 PHASE3
NCT00232661 COMPLETED
Breast Cancer
AstraZeneca
 2000-08 PHASE3
NCT00002528 COMPLETED
Breast Cancer
ETOP IBCSG Partners Foundation
 1993-05 PHASE3
NCT00005822 COMPLETED
Breast Cancer
Case Comprehensive Cancer Center
 2000-04 PHASE1
NCT00002777 COMPLETED
Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
 1996-05 PHASE3
NCT00026286 COMPLETED
Breast Cancer; Hot Flashes; Menopausal Symptoms
Eastern Cooperative Oncology Group
 2000-11-28 PHASE3
NCT00005886 COMPLETED
Breast Cancer
University of Kansas Medical Center
 2000-07 PHASE1
NCT00002707 COMPLETED
Breast Cancer
NSABP Foundation Inc
 1995-12 PHASE3
NCT00014638 COMPLETED
Breast Cancer
Novartis
 2001-01 PHASE4
NCT00002679 COMPLETED
Breast Cancer
Yale University
 1994-02 PHASE2
NCT00003953 COMPLETED
Breast Cancer
Case Comprehensive Cancer Center
 1999-02 PHASE2
NCT00849030 COMPLETED
Breast Cancer
AstraZeneca
 1996-07 PHASE3
NCT00003035 COMPLETED
Breast Cancer
Georgetown University
 1997-03 PHASE2
NCT00003080 COMPLETED
Ovarian Cancer
Fred Hutchinson Cancer Center
 1996-09 PHASE1
NCT00003032 COMPLETED
Breast Cancer
NCIC Clinical Trials Group
 1997-04-25 PHASE3
NCT00002644 COMPLETED
Breast Cancer
Queen Mary University of London
 1994-01 PHASE3
NCT00002680 COMPLETED
Breast Cancer
Yale University
 1994-02 PHASE2
NCT00003099 COMPLETED
Breast Cancer
M.D. Anderson Cancer Center
 1996-05 PHASE2
NCT00003424 COMPLETED
Liver Cancer
National Medical Research Council (NMRC), Singapore
 1997-04 PHASE3
NCT00003050 COMPLETED
Breast Cancer
University of Southern California
 1997-04 PHASE2
NCT00590785 COMPLETED
High Risk; Breast Cancer; Positive Nodes; Cyclophosphamide; Doxorubicin
National Cancer Institute (NCI)
 1996-08-13 PHASE3
NCT00309491 COMPLETED
Early-stage Breast Cancer
Austrian Breast & Colorectal Cancer Study Group
 1990-12 PHASE3
NCT00034125 COMPLETED
Breast Neoplasms
Eli Lilly and Company
 PHASE3
NCT00001378 COMPLETED
Breast Cancer; Breast Neoplasms
National Cancer Institute (NCI)
 1994-01 PHASE1
NCT00398489 UNKNOWN
Breast Cancer
Technical University of Munich
 2006-10 PHASE2
NCT00006030 UNKNOWN
Breast Cancer
British Association of Surgical Oncology: Breast Group
 1992-01 PHASE3
NCT00052728 COMPLETED
Breast Cancer
National Cancer Institute (NCI)
 2002-12 PHASE2
NCT00449514 UNKNOWN
Infertility
Shaare Zedek Medical Center
 2007-05
NCT00126464 UNKNOWN
Breast Cancer
Cedars-Sinai Medical Center
 2004-11
NCT00003678 UNKNOWN
Breast Cancer
University Hospital Birmingham
 1991-05 PHASE3
NCT00210028 TERMINATED
Breast Neoplasms
Institut Claudius Regaud
 2003-08 PHASE2
NCT00032136 COMPLETED
Breast Cancer
Cancer Research Campaign Clinical Trials Centre
 2001-12 PHASE3
NCT00002581 COMPLETED
Breast Cancer
Scottish Cancer Therapy Network
 1993-06 PHASE3
NCT00411203 COMPLETED
Bipolar Disorder
Stanley Medical Research Institute
 2003-04 PHASE3
NCT00003418 UNKNOWN
Breast Cancer
International Collaborative Cancer Group
 1998-02 PHASE3
NCT00189358 COMPLETED
Ovarian Cancer; Cancer of the Fallopian Tube; Peritoneal Cancer
AGO Study Group
 PHASE2
NCT00784862 COMPLETED
Breast Cancer
AstraZeneca
 1998-06 PHASE3
NCT00002608 COMPLETED
Adrenocortical Carcinoma; Brain and Central Nervous System Tumors; Head and Neck Cancer; Liver Cancer; Malignant Mesothelioma; Pheochromocytoma; Sarcoma
Ottawa Regional Cancer Centre
 1994-05 PHASE2
NCT00002579 COMPLETED
Breast Cancer
Scottish Cancer Therapy Network
 1993-03 PHASE3
NCT00003013 COMPLETED
Breast Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
 1996-10 PHASE3
NCT00287534 COMPLETED
Breast Cancer
AstraZeneca
 1996-11 PHASE2
NCT00440349 UNKNOWN
Retroperitoneal Fibrosis
University of Parma
 2000-10 PHASE2
NCT00000529 COMPLETED
Cardiovascular Diseases; Coronary Disease; Heart Diseases; Hypertension; Myocardial Ischemia
NSABP Foundation Inc
 1992-05 PHASE3
NCT00006369 UNKNOWN
Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
 2000-06 PHASE2
NCT00002755 COMPLETED
Breast Cancer
Scottish Cancer Therapy Network
 1995-11 PHASE3
NCT00003016 UNKNOWN
Breast Cancer
University of Oxford
 1995-10 PHASE3
NCT00543829 COMPLETED
Breast Neoplasms
GBG Forschungs GmbH
 1998-04 PHASE2
NCT00214110 COMPLETED
Amyotrophic Lateral Sclerosis (ALS)
University of Wisconsin, Madison
 2001-01 PHASE2
NCT00003680 UNKNOWN
Breast Cancer
Scottish Cancer Therapy Network
 1998-11 PHASE3
NCT00001436 COMPLETED
Neoplasm Metastasis; Osteosarcoma
National Cancer Institute (NCI)
 1995-05 PHASE1
NCT00784680 COMPLETED
Quality of Life
AstraZeneca
 1998-04 PHASE3
NCT00295100 COMPLETED
Breast Cancer
University of Pennsylvania
 2000-09 PHASE2
NCT00286117 COMPLETED
Breast Cancer
AstraZeneca
 1998-03 PHASE3
NCT00002460 UNKNOWN
Breast Cancer
Cancer Research UK
 1987-09 PHASE3
NCT00810706 TERMINATED
Breast Cancer
Hellenic Breast Surgeons Society
 2001-04 PHASE3
NCT00793377 COMPLETED
Primary Breast Cancer
GBG Forschungs GmbH
 PHASE3
NCT00002967 COMPLETED
Breast Cancer
NSABP Foundation Inc
 1997-05 PHASE3
NCT00003679 UNKNOWN
Breast Cancer
Scottish Cancer Therapy Network
 1998-11 PHASE3
NCT00002720 COMPLETED
Breast Cancer
European Institute of Oncology
 1995-12 PHASE3
NCT00002582 COMPLETED
Breast Cancer
Institute of Cancer Research, United Kingdom
 1993-06 PHASE3
NCT00375622 COMPLETED
Hereditary Hemorrhagic Telangiectasia
Rabin Medical Center
 2005-02 PHASE2
NCT00026585 COMPLETED
Bipolar Disorder
National Institute of Mental Health (NIMH)
 2001-11-09 PHASE2
NCT00002580 COMPLETED
Breast Cancer
Scottish Cancer Therapy Network
 1993-06 PHASE3
NCT00001504 COMPLETED
Breast Cancer; Breast Neoplasm
National Cancer Institute (NCI)
 1996-05 PHASE1
NCT00053339 WITHDRAWN
Stage IV Breast Cancer; Recurrent Breast Cancer
Alliance for Clinical Trials in Oncology
 PHASE3
NCT00010140 UNKNOWN
Breast Cancer
International Collaborative Cancer Group
 1997-08 PHASE3
NCT00024336 UNKNOWN
Brain and Central Nervous System Tumors
Children's Cancer and Leukaemia Group
 1999-08 PHASE2
NCT00033683 UNKNOWN
Breast Cancer
Institute of Cancer Research, United Kingdom
 2001-02 PHASE2
NCT00814125 COMPLETED
Breast Cancer
AstraZeneca
 1997-06 PHASE3
NCT00632723 COMPLETED
Breast Cancer
AstraZeneca
 2001-04 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-12)

Check the Tamoxifen product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Tamoxifen selectively binds to estrogen receptors, competitively blocking estrogen binding to inhibit target gene transcription, disrupt downstream mitotic signaling pathways, and induce tumor cell apoptosis. This targeted inhibition of estrogen-driven growth directly underpins its therapeutic application in estrogen receptor-positive breast cancers and other hormone-responsive malignancies studied in clinical settings.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.